晚期肿瘤病人使用小剂量阿片类药物中毒1例

2019-08-10 李雪 赵庆国 中国疼痛医学杂志

男性,60岁。2017年7月因“肝占位2月余”入院,入院一周后自诉间断腹胀,后腹胀症状逐渐加重,腹部超声提示腹水,行腹腔穿刺提示肝癌破裂出血伴腹腔感染,实验室检查:ALB30g/L,DBIL71.2μmol/L,TBIL82.6μmol/L,ALT24U/L,AST139U/L,r-GGT178U/L,Scr317μmol/L,NH326.4μmol/L。给予对症治疗后出血及腹腔感染均控制,精神可

1.病例介绍
 
男性,60岁。2017年7月因“肝占位2月余”入院,入院一周后自诉间断腹胀,后腹胀症状逐渐加重,腹部超声提示腹水,行腹腔穿刺提示肝癌破裂出血伴腹腔感染,实验室检查:ALB30g/L,DBIL71.2μmol/L,TBIL82.6μmol/L,ALT24U/L,AST139U/L,r-GGT178U/L,Scr317μmol/L,NH326.4μmol/L。给予对症治疗后出血及腹腔感染均控制,精神可,再次复查:ALB28g/L,DBIL64.1μmol/L,TBIL72.6μmol/L,ALT19U/L,AST71U/L,r-GGT70U/L,Scr225μmol/L,NH320.9μmol/L。
 
病人出现肝区间断性疼痛,考虑与肝内多发病灶有关,疼痛数字评分法(numerical rating scale,NRS)评分6~7分,给予口服洛芬待因缓释片2片Q12h,用药3天后复查血:DBIL51.5μmol/L,DBIL56.6μmol/L,ALT18U/L,AST116U/L,r-GGT80U/L,Scr312μmol/L,NH323.9μmol/L。由于疼痛控制不佳,换用口服盐酸羟考酮缓释片10mgQ12h,疼痛控制可,但用药3天后病人出现嗜睡,呼之能应,查体可见针尖样瞳孔,直径约1mm,体温:36.4度,脉搏:101次,呼吸:7次,血压:120/62mmHg。急查血象、肝肾功能、电解质、血氨、头颅CT等,排除感染、肝性脑病、颅脑出血或占位性病变等因素。予以停用盐酸羟考酮缓释片,持续低流量吸氧,给予盐酸纳洛酮注射液解救,1小时后病人瞳孔扩大,直径约2mm,测脉搏:98次,呼吸:14次,血压:119/61mmHg。
 
停药后第二天,病人神志清楚,精神可,无嗜睡,查体瞳孔等大等圆,直径约3mm,对光反射灵敏,呼吸16次,脉搏96次,血压134/65mmHg。
 
2.讨论
 
阿片类药物在肿瘤病人中应用广泛,如手术的辅助麻醉、术后疼痛控制和晚期癌痛的治疗等。当误用、一次性使用剂量过大或者肝肾功能不全时,可能会出现阿片类药物中毒。轻度或中度中毒病人会出现嗜睡、针尖样瞳孔、血压和脉搏下降、肠鸣音减弱等,严重中毒会出现昏迷伴有呼吸抑制和呼吸暂停。
 
临床上,阿片类药物最严重的不良反应就是呼吸抑制,由于该类药物受很多综合因素(年龄、性别、体重指数、意识状态、并存的疾病、合并应用其他药物、基因多态性等)的影响,导致不能准确地预测呼吸抑制发生的时间及严重程度。有国内报道,病人使用吗啡控释片30mg出现了呼吸抑制的表现;而国外报道,每天服用吗啡控释片剂量达到3600mg,却未见明显不良反应。
 
本例病人初始镇痛方案使用洛芬待因缓释片,该药为布洛芬和可待因组成的复方制剂,布洛芬为非甾体抗炎药,通过抑制环氧化酶对痛源的炎症组织起局部镇痛作用,属于第一阶梯镇痛药,镇痛作用相对较弱,而可待因为弱阿片类镇痛药,需要在肝脏代谢成吗啡而发挥镇痛作用。该病人机体功能以及肝肾功能较差,可待因在体内可能无法完全转换为吗啡,而且NRS评分6~7分属于中重度疼痛,故使用第二阶梯药物洛芬待因缓释片镇痛效果不佳,另外,可待因及其代谢产物主要是通过肾脏排泄,该病人肌酐清除率低,可能会进一步增加肾脏负担和阿片类药物的毒副反应。用药3天后由于疼痛控制不佳,且血肌酐较前升高,换用盐酸羟考酮缓释片。
 
羟考酮为阿片受体纯激动剂,口服吸收良好,具有生物利用度高,镇痛效果好,毒副反应小等特点。盐酸羟考酮缓释片是即释和控释双重作用的剂型,即释相达峰迅速,38%的药物快速释放,1h内快速镇痛;控释相药效持久,62%的药物精确、缓慢释放,12h平稳持续镇痛。该药在轻中度肝功能不全病人中,羟考酮的应用是比较安全的,但是对于重度肝功能不全病人来说,羟考酮血药浓度变化较大,需要调整药物剂量为原来的2/3~1/2;另外,对于轻中度肾功能不全病人来说,由于羟考酮的代谢产物不具备活性,故与吗啡相比,相对安全,但仍需根据临床反应和肾小球滤过率调整剂量。
 
本例病人给予盐酸羟考酮缓释片后出现嗜睡、针尖样瞳孔、呼吸减弱等阿片类药物中毒症状,分析原因:①病人营养差,且前段时间出现肿瘤破裂出血以及腹腔感染,虽都已控制,但整个机体功能下降。②虽然羟考酮在轻中度肝功能不全病人中应用相对安全,但病人肝内多发转移,肝硬化失代偿期,肝脏代谢能力较正常人差,故这也是导致中毒的原因之一。③病人肾功能差,肌酐清除率低,不能有效的将阿片类药物及代谢产物排出,使得药物在体内蓄积,血药浓度比肾功能正常时高,而病人疼痛状态又未能达到相应程度,故出现中毒症状。
 
该病例提示我们,对于中重度的癌痛病人,初始方案应弱化二阶梯治疗,对于肝肾功能差的病人,选择阿片类药物需慎重,应避免选择可待因。另外,虽然使用小剂量阿片类药物,也应根据病人的实际情况,如机体状况、肝功能、肾小球滤过率等指标,随时调整用药剂量,避免因药物代谢等问题而导致中毒,同时应密切观察所有使用阿片类药物的病人用药后呼吸情况、瞳孔反应等,早发现、早治疗,保障病人用药安全。
 
原始出处:

李雪,赵庆国.晚期肿瘤病人使用小剂量阿片类药物中毒1例[J].中国疼痛医学杂志,2018,24(08):639-640.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-10-24 pyaili
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 lhlxtx
  6. [GetPortalCommentsPageByObjectIdResponse(id=2043609, encodeId=22c3204360960, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Oct 24 16:13:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026208, encodeId=6eeb202620838, content=<a href='/topic/show?id=5e3d8e6465f' target=_blank style='color:#2F92EE;'>#药物中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87646, encryptionId=5e3d8e6465f, topicName=药物中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Tue Jan 28 06:13:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709471, encodeId=30561e094712b, content=<a href='/topic/show?id=cf4a598e795' target=_blank style='color:#2F92EE;'>#晚期肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59877, encryptionId=cf4a598e795, topicName=晚期肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926b31711313, createdName=ms705947299214030, createdTime=Mon Jun 22 18:13:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253093, encodeId=3eaf1253093f1, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309136, encodeId=cf7f1309136ad, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319118, encodeId=377713191182d, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 12 07:13:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 mashirong

相关资讯

JCO:晚期肿瘤患者心理干预

晚期肿瘤患者通常会因为疾病负担和即将面临的死亡而出现持续的压力增加。管理肿瘤并有意义的生活(CALM)是一种简洁的人性化的心理治疗措施,主要用于预防和治疗晚期肿瘤患者面临的死亡压力。JCO近期发表了一篇文章,比较CALM和常规护理(UC)在晚期肿瘤患者中的效果。

CLIN CANCER RES:LY2940680治疗晚期肿瘤

CLIN CANCER RES近期发表了一篇文章,研究LY2940680(taladegib)治疗局部晚期/转移肿瘤患者的推荐Ⅱ期剂量及安全的给药方案。

BJC:NUC-1031治疗晚期肿瘤

吉西他滨可用于治疗多种肿瘤,但其疗效受肿瘤细胞耐药的限制。NUC-1031是吉西他滨的氨基磷酸酯修饰物,被设计用于克服这些关键的耐药机制。BJC近期发表了一篇文章, 报道了NUC-1301治疗晚期肿瘤的临床试验结果。

CLIN CANCER RES:Utomilumab单药治疗晚期肿瘤

动物模型中进行的临床前实验证明免疫共刺激分子4-1BB/CD137的激动剂可以增强细胞毒T细胞和NK细胞的活性,诱导有力的抗肿瘤反应。Utomilumab(PF-05082566)是免疫共刺激分子4-1BB/CD137的激动性单抗。CLIN CANCER RES近期发表了一篇文章,评估Utomilumab治疗晚期恶性肿瘤的安全性、耐受性、药代动力学和药效学。

CLIN CANCER RES:LY3023414治疗晚期肿瘤患者

PI3K/mTOR通路在肿瘤中通常出现异常。LY3023414是Ⅰ类PI3K亚型,mTOR和DNA-PK的选择性抑制剂。CLIN CANCER RES近期发表了一篇文章,报道了LY3023414的Ⅰ期临床试验结果。

ANN ONCOL:LY3039478治疗晚期或转移性肿瘤

由于配体和/或受体的突变或过表达引起的失调的Notch信号传导涉及各种人恶性肿瘤。γ-分泌酶抑制剂通过影响Notch蛋白的跨膜结构域抑制Notch信号传导。LY3039478是一种新型强效Notch抑制剂,可抑制Notch信号传导及其下游生物学效应。JCO近期发表了一篇文章,报道了LY3039478治疗晚期或转移性肿瘤症患者的安全性,药代动力学,药效学效应和抗肿瘤活性。